GLP-1 Receptor Agonists Models for Type 1 Diabetes: A Narrative Review.

IF 4.1 Q2 ENDOCRINOLOGY & METABOLISM

Journal of Diabetes Science and Technology Pub Date : 2024-10-16 DOI:10.1177/19322968241285925

Clara Furió-Novejarque, José-Luis Díez, Jorge Bondia

{"title":"GLP-1 Receptor Agonists Models for Type 1 Diabetes: A Narrative Review.","authors":"Clara Furió-Novejarque, José-Luis Díez, Jorge Bondia","doi":"10.1177/19322968241285925","DOIUrl":null,"url":null,"abstract":"Background: Glucagon-like peptide 1 (GLP-1) is a hormone that promotes insulin secretion, delays gastric emptying, and inhibits glucagon secretion. The GLP-1 receptor agonists have been developed as adjunctive therapies for type 2 diabetes to improve glucose control. Recently, there has been an interest in introducing GLP-1 receptor agonists as adjunctive therapies in type 1 diabetes alongside automatic insulin delivery systems. The preclinical validation of these systems often relies on mathematical simulators that replicate the glucose dynamics of a person with diabetes. This review aims to explore mathematical models available in the literature to describe GLP-1 effects to be used in a type 1 diabetes simulator.Methods: Three databases were examined in the search for GLP-1 mathematical models. More than 1500 works were found after searching for specific keywords that were narrowed down to 39 works for full-text assessment.Results: A total of 23 works were selected describing GLP-1 pharmacokinetics and pharmacodynamics. However, none of the found models was designed for type 1 diabetes. An analysis is included of the available models' features that could be translated into a GLP-1 receptor agonist model for type 1 diabetes.Conclusion: There is a gap in research in GLP-1 receptor agonists mathematical models for type 1 diabetes, which could be incorporated into type 1 diabetes simulators, providing a safe and inexpensive tool to carry out preclinical validations using these therapies.","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968241285925"},"PeriodicalIF":4.1000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571630/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes Science and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/19322968241285925","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Glucagon-like peptide 1 (GLP-1) is a hormone that promotes insulin secretion, delays gastric emptying, and inhibits glucagon secretion. The GLP-1 receptor agonists have been developed as adjunctive therapies for type 2 diabetes to improve glucose control. Recently, there has been an interest in introducing GLP-1 receptor agonists as adjunctive therapies in type 1 diabetes alongside automatic insulin delivery systems. The preclinical validation of these systems often relies on mathematical simulators that replicate the glucose dynamics of a person with diabetes. This review aims to explore mathematical models available in the literature to describe GLP-1 effects to be used in a type 1 diabetes simulator.

Methods: Three databases were examined in the search for GLP-1 mathematical models. More than 1500 works were found after searching for specific keywords that were narrowed down to 39 works for full-text assessment.

Results: A total of 23 works were selected describing GLP-1 pharmacokinetics and pharmacodynamics. However, none of the found models was designed for type 1 diabetes. An analysis is included of the available models' features that could be translated into a GLP-1 receptor agonist model for type 1 diabetes.

Conclusion: There is a gap in research in GLP-1 receptor agonists mathematical models for type 1 diabetes, which could be incorporated into type 1 diabetes simulators, providing a safe and inexpensive tool to carry out preclinical validations using these therapies.

查看原文本刊更多论文

治疗 1 型糖尿病的 GLP-1 受体激动剂模型：叙述性综述。

背景：胰高血糖素样肽 1（GLP-1）是一种促进胰岛素分泌、延缓胃排空和抑制胰高血糖素分泌的激素。GLP-1 受体激动剂已被开发为 2 型糖尿病的辅助疗法，以改善血糖控制。最近，人们开始关注将 GLP-1 受体激动剂与胰岛素自动给药系统一起作为 1 型糖尿病的辅助疗法。这些系统的临床前验证通常依赖于复制糖尿病患者血糖动态的数学模拟器。本综述旨在探讨文献中描述 GLP-1 作用的数学模型，以用于 1 型糖尿病模拟器：方法：在三个数据库中搜索 GLP-1 数学模型。方法：在三个数据库中搜索 GLP-1 数学模型，在搜索特定关键词后发现了 1500 多篇文献，最后筛选出 39 篇文献进行全文评估：结果：共筛选出 23 篇描述 GLP-1 药代动力学和药效学的文章。结果：共选取了 23 篇描述 GLP-1 药代动力学和药效学的文章，但所发现的模型都不是针对 1 型糖尿病设计的。本文分析了现有模型的特点，这些特点可转化为适用于 1 型糖尿病的 GLP-1 受体激动剂模型：结论：1 型糖尿病 GLP-1 受体激动剂数学模型的研究存在空白，可将其纳入 1 型糖尿病模拟器，为使用这些疗法进行临床前验证提供安全、廉价的工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Diabetes Science and Technology Medicine-Internal Medicine

CiteScore

7.50

自引率

12.00%

发文量

148

期刊介绍： The Journal of Diabetes Science and Technology (JDST) is a bi-monthly, peer-reviewed scientific journal published by the Diabetes Technology Society. JDST covers scientific and clinical aspects of diabetes technology including glucose monitoring, insulin and metabolic peptide delivery, the artificial pancreas, digital health, precision medicine, social media, cybersecurity, software for modeling, physiologic monitoring, technology for managing obesity, and diagnostic tests of glycation. The journal also covers the development and use of mobile applications and wireless communication, as well as bioengineered tools such as MEMS, new biomaterials, and nanotechnology to develop new sensors. Articles in JDST cover both basic research and clinical applications of technologies being developed to help people with diabetes.